Downloads

We provide consulting and contract development services for vaccine products.  We have expertise and facilities to assist in development of your vaccine product.  This includes small scale antigen fermentation and purification, formulation development including adjuvantation and stabilization, as well as filling of final drug product. 

VaxForm's current R&D program

• Oral SARS-CoV-2 Vaccine
• Oral DTaP Vaccine
• Vaccine targeting Streptococcus pyogenes  

• Burlet, E.; Thomas, N.; Carwell, S.; Gershman, B.W.; Morefield, G.L. Formulation Attributes Impact Immune Profile of an Oral and Thermostable COVID-19 Subunit Vaccine. Vaccines 2024, 12, 1087.
• Troese, M.J.; Burlet, E.; Cunningham, M.W.; Alvarez, K.; Bentley, R.; Thomas, N.; Carwell, S.; Morefield, G.L. Group A Streptococcus Vaccine Targeting the Erythrogenic Toxins SpeA and SpeB Is Safe and Immunogenic in Rabbits and Does Not Induce Antibodies Associated with Autoimmunity. Vaccines 2023, 11, 1504 
• Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes. E.Burlet, H.HogenEsch, A.Dunham, G.Morefield. The AAPS Journal 19:2017
• Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant. Harm HogenEsch, Anisa Dunham, Elodie Burlet, Fangjia Lu, Yung-Yi C. Mosley and Garry Morefield. J. Appl. Toxicol., doi: 10.1002/jat.3349.
• Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes. G Morefield, G Touhey, F Lu, A Dunham, and H HogenEsch. Vaccine 32:3810-3815, 2014.
• A Rational, Systematic Approach for the Development of Vaccine Formulations. Morefield G. The AAPS Journal. 13(2): 191-200, 2011.